Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

AACR 2016 /
Galectins in tumour immunity

16th - 20th Apr 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 05.05.16
Views: 1833

Dr Gabriel Rabinovich - Instituto de Biología y Medicina Experimental, Buenos Aires, Argentina

Dr Gabriel Rabinovich meets with ecancertv at AACR 2016 to discuss galectins.

Galectin 1, secreted by tumour cells, kills T cells and promotes non-immunogenic tumourous dendritic cell growth.

Beyond immune suppression, galectins are also linked to angiogenesis, which further promotes the persistence of the tumour microenvironment.

Dr Rabinovich reports on the current trials of galectin targeted therapy, and his upcoming research.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation